Considering Safety of Gene Therapy for Retinal Diseases


Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.


Experts continue their discussion on the potential of gene therapy; in particular, they explore the exciting prospect of developing an ocular biofactory within a patient's eye to produce a VEGF inhibitor. Diana Do, MD expresses enthusiasm for gene therapy but raises a critical point about the long-term safety concerns of these specialized delivery systems. She emphasizes the inability to “turn off” gene therapy and highlights the need to understand the implications of chronic VEGF suppression within the eye over an extended period. David Eichenbaum, MD acknowledges the importance of addressing safety concerns associated with gene therapy, including inflammation and adverse events.

This summary was AI-generated and edited for clarity.

Related Videos
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.